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ABSTRACT: Inactivating mutations in TSC1 and TSC2
cause tuberous sclerosis complex (TSC). The 2012 inter-
national consensus meeting on TSC diagnosis and manage-
ment agreed that the identification of a pathogenic TSC1
or TSC2 variant establishes a diagnosis of TSC, even in
the absence of clinical signs. However, exons 25 and 31 of
TSC2 are subject to alternative splicing. No variants caus-
ing clinically diagnosed TSC have been reported in these
exons, raising the possibility that such variants would not
cause TSC. We present truncating and in-frame variants
in exons 25 and 31 in three individuals unlikely to ful-
fil TSC diagnostic criteria and examine the importance of
these exons in TSC using different approaches. Amino
acid conservation analysis suggests significantly less con-
servation in these exons compared with the majority of
TSC2 exons, and TSC2 expression data demonstrates that
the majority of TSC2 transcripts lack exons 25 and/or 31
in many human adult tissues. In vitro assay of both ex-
ons shows that neither exon is essential for TSC complex
function. Our evidence suggests that variants in TSC2 ex-
ons 25 or 31 are very unlikely to cause classical TSC,
although a role for these exons in tissue/stage specific de-
velopment cannot be excluded.
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Introduction
Tuberous sclerosis complex (TSC) is an autosomal-dominant
disease caused by inactivating mutations in either TSC1 (MIM
#605284) or TSC2 (MIM #191092). TSC disease severity is variable
with signs and symptoms ranging from hypomelanotic macules, to
epilepsy, intellectual disability, autism, andmultiple hamartomas in
kidney, brain, heart, and lung. In TSC, about 70%of cases are due to
newmutations [Sampson et al., 1989; Osborne et al., 1991; Au et al.,
2007] and this presents a challenge for molecular diagnostics espe-
cially when the variant identified is not obviously disease causing.
For example, some missense changes in TSC2 have been associated
with TSC in patients diagnosed with definite TSC [Sancak et al.,
2005; Hoogeveen-Westerveld et al., 2011], as well as cases in which
symptoms are less severe and TSC is more often likely to be familial
[Khare et al., 2001; O’Connor et al., 2003; Mayer et al., 2004; Jansen
et al., 2006; Wentink et al., 2012].
Although there are well-defined clinical diagnostic criteria for
TSC [Northrup et al., 2013], it can still be difficult to establish a
clinical diagnosis of TSC, particularly in young patients who do not
yet exhibit typical TSC lesions, but may have severe but nonspecific
symptoms such as epilepsy, intellectual disability, and/or autism. In
these cases, a molecular diagnosis can be helpful. Indeed, the iden-
tification of a clearly inactivating TSC1 or TSC2mutation is consid-
ered sufficient evidence for a diagnosis of TSC, even in the absence of
clinical signs [Northrup et al., 2013]. Increasingly, next-generation
sequencing (NGS) ofTSC1,TSC2, andmany other genes simultane-
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ously (gene panels, whole-genome [WGS] or whole-exome [WES]
sequencing) is being used in diagnostic settings. NGS is also applied
to population genetics in large-scale sequencing studies, such as the
NHLBIGOExome Sequencing Project with data in the ExomeVari-
ant Server (EVS) and the Exome Aggregation Consortium (ExAC).
In these studies, TSC is not assessed and the available phenotype
data are very limited. This reliance on molecular diagnosis makes
it even more important that the interpretation of any apparently
pathological variant is correct.
The main recognized challenge to the molecular diagnosis of
TSC has been (and still is) the “Variants of Uncertain Significance”
(VUS), many of these being missense and in-frame indels. The
TSC1 and TSC2 genes encode core components of the TSC protein
complex that is a critical negative regulator of the mechanistic tar-
get of rapamycin (mTOR) complex 1 (TORC1) [Dibble and Man-
ning, 2013]. In vitro assays to determine the effects of TSC1 and
TSC2missense and in-frame indels on TORC1 activity have proven
useful in the ascertainment of the pathogenicity of variants previ-
ously reported as VUS [Hoogeveen-Westerveld et al., 2011, 2013;
Dunlop et al., 2011]. In these tests, assay results are summarized
as the effect of the variants on the “TSC complex function” by
which we mean “the inhibition of TORC1 activity.” An additional
option for evaluating a VUS is to perform conservation analysis
of orthologous protein sequences in multiple species. Several com-
putational algorithms (e.g., PolyPhen, SIFT) incorporate protein
alignments from multiple species into the evaluation of the effects
of amino acid substitutions on protein function [Ng and Henikoff,
2003; Adzhubei et al., 2013]. In our experience, these algorithms
were not reliable enough to classify individual VUS with confidence
[Hoogeveen-Westerveld et al., 2011]. However, this approach may
still be applicable where high-quality alignments of multiple species
are utilized. Conservation analysis has been utilized as a secondary
line of evidence in the classification of VUS in the BRCA1/2 genes
[Eggington et al., 2014].
The TSC1 and TSC2 Leiden Open Variation Databases (TSC
LOVD) were made publicly available in 2006 and the TSC2 LOVD
now displays 2,232 different variants (November 13, 2015), with a
further 300 variants available on querying. Of these 2,532 differ-
ent variants, about half are considered to be certainly or probably
pathogenic. All 41 coding TSC2 exons, except exons 25 and 31, in-
clude both obviously truncating variants and fully confirmed mis-
sense variants that cause tuberous sclerosis. These two exons (25 and
31) have been shown to undergo alternative splicing inmany tissues
[Xiao et al., 1995; Xu et al., 1995; Olsson et al., 1996], although
the extent and clinical significance of this is unclear. So far, we are
not aware of confirmed reports of any pathological variants in these
two exons in TSC cases. We have questioned the meaning of this
observation over the 10 years of curating the TSC LOVD. To inves-
tigate the implications of this finding, we conducted function tests
to assay expression constructs that lacked sequences correspond-
ing to whole TSC2 exons, before the cases with truncating variants
described below came to our attention.
As curators of the TSC LOVD, we are often asked to assist in clas-
sifying new TSC1 and TSC2 variants and we recently encountered a
frameshift variant in TSC2 exon 25 and a nonsense variant in TSC2
exon 31, in individuals who had not been diagnosed with TSC and
as described below (cases 1 and 2) were unlikely to have the disease.
Finding these two stop codons triggered further investigationson the
two exons and we gathered existing evidence that might help clarify
the significance of exons 25 and 31 in TSC. During our investiga-
tions, we became aware of an individual with an in-frame deletion
in TSC2 exon 31 (case 3 below). None of our three cases met the
diagnostic criteria for TSC. Therefore, to gain insight into the sig-
nificance of these variants in TSC, we reviewed all variants mapping
to exons 25 and 31 in the TSC2 LOVD (http://www.lovd.nl/TSC2),
performed conservation analysis, reviewed TSC2 mRNA expres-
sion data, and conducted in vitro functional analysis. We conclude
that TSC2 exons 25 and 31 are not required for the TSC complex-
dependent inhibition of TORC1 and that variants in these exons are
unlikely to cause TSC.
Materials and Methods
TSC2 Exon and Variant Nomenclature
TSC2 (GenBank NG 005895.1 GI:125662814) consists of 42
exons, including a 5’ noncoding exon [ftp://ftp.ebi.edu.au/pub/
databases/lrgex/LRG_487.xml]. However, the TSC community usu-
ally number TSC2 exons from the start of the protein coding se-
quence making 41 exons in total, with the 5’ noncoding exon num-
bered 1a. This convention is used here.
Nucleotide numbering corresponds to the TSC2 cDNA sequence
(GenBank NM 000548.3, GI:116256351) with +1 as A of the ATG
translation initiation codon in the reference sequence, and the ini-
tiation codon as codon 1.
Patients and Variants
Case 1: Apredictednonsense variant inTSC2 exon 25 (c.2859dup,
p.K954Qfs∗6)was identified inanepilepsygenepanel test performed
on DNA from a 10-year-old patient with epilepsy, but no clinical or
radiographic findings supporting a diagnosis of TSC. The variant
was reported as “pathogenic.”
Case 2: We analyzed rare (frequency <0.005) TSC1 and TSC2
variants identified in 1,805 individuals who had their whole ex-
ome sequenced as part of the UK10K project [UK10K Consortium
et al.,2015]. Study participants consented to be included as con-
trols for diseases that were not directly under study. As part of the
search for “incidental findings” that might cause serious inherited
disease we received 67 rare variants to assess. These included a pre-
dicted nonsense variant in TSC2 exon 31 (c.3837C>G, p.Y1279∗).
The only accessible information on this individual is that they were
recruited for a diabetes study. This variant is reported in the UK10K
publication [UK10K Consortium et al., 2015].
Case 3: We identified an African American individual with
intractable neonatal onset epilepsy and profound developmen-
tal delay, and an in-frame deletion in TSC2 exon 31 (TSC2
c.3846 3855delinsG, p.S1282 G1285delinsR). This individual also
carries the TSC2 c.4007C>T (p.S1336L, exon 33) variant that
has a minor allele frequency of 0.137%–0.296% in the African
population (rs148527903; http://evs.gs.washington.edu/EVS/ and
http://exac.broadinstitute.org/). Both variants were reported as
“possibly pathogenic.” The individual has two cafe´ au lait spots,
normal renal imaging, normal ophthalmology examination, no hy-
popigmented macules, and no brain MRI findings characteristic
of TSC (no tubers, subependymal nodules, or areas of cortical
dysplasia). A possible cardiac rhabdomyoma was detected on an
echocardiogram obtained after the genetic test result. The most re-
cent MRI at 4 years 9 months still shows no stigmata of TSC. TSC2
c.3846 3855delinsG was inherited from a parent (32 years old) who
has also been seen at the TSC clinic. The parent has a single hy-
popigmented macule, but no obvious stigmata of TSC. Of note is a
different TSC2 exon 31 variant (TSC2 c.3846 3854del) that is pre-
dicted to encode an identical protein (p.S1282 G1285delinsR). This
variant was reported in a large-scale WES study of individuals with
autism spectrum disorder and epilepsy [Schaaf et al., 2011].
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Conservation Analysis and Variants in TSC2 Exons 25 and 31
To assess the conservation of TSC2 exons 25 and 31 and review
the classification of variants within these two exons, a manual align-
ment of 163 orthologous vertebrate TSC2 protein sequences was
constructed. For the comparison of conservation in exons 25 and
31 to other TSC2 exons, we performed a simple mathematical anal-
ysis and a more comprehensive statistical analysis using Scorecons
[Valdar, 2002] and Wilcoxon Rank-Sum test [R Core Team, 2015].
The classification of all variants inTSC2 exons 25 and 31 reported
to us (http://www.lovd.nl/TSC2) were reviewed.
Expression Analysis
Literature searches were performed and data in the
NCBI (http://www.ncbi.nlm.nih.gov/gene/7249) and Genotype-
Tissue Expression (GTEx) databases (http://www.gtexportal.
org/home/) were used for expression analyses. A multiple tran-
script sequence alignment was performed using Clustal Omega
(http://www.ebi.ac.uk/Tools/msa/clustalo/).
Functional Analysis
To assess the functional importance of exons 25 and 31, TSC2
expression constructs with in-frame deletions of sequences corre-
sponding to specific exonswere derived from the original full-length
TSC2 expression construct containing exon 25 but lacking exon 31
[Nellist et al., 2005]. Site-directed mutagenesis (SDM) was used
to delete these sequences. Expression constructs lacking exons 3,
4, 5, 6, 9, 12, 19, 22, and 41 served as controls for the expression
construct lacking exon 25. To derive a TSC2 expression construct
containing exon 31 (referred to as +ex31) an Eco47III fragment
from a partial cDNA clone containing exon 31 was cloned into
the original TSC2 expression construct. The p.R611Q (exon 16),
p.S1282 G1285delinsR (exon 31), and p.S1336L (exon 33) variants
were derived from the +ex31 expression construct by SDM. For
each construct, the entire TSC2 open-reading frame was checked
by sequencing to ensure that no additional nucleotide changes were
introduced by the SDM procedure. A standard functional assay
[Hoogeveen-Westerveld et al., 2011] was applied to determine the
effects of the variants on TSC2 protein stability (estimated from
the TSC2 protein signal), the TSC1-TSC2 protein interaction (es-
timated from the TSC1 signal), and on TORC1 activity (estimated
from the ratio of T389-phosphorylated p70 S6 kinase (S6K): total
S6K).
Results
Conservation Analysis and Pathogenicity of Variants in
TSC2 Exons 25 and 31
TSC2 exons 25 and 31 are conserved in vertebrates down to
the lamprey (Supp. Fig. S1, A and B). The TSC2 LOVD contains
17 different variants (excluding contiguous exon deletions) map-
ping to TSC2 exon 25, or to the adjacent intronic sequences; 14
of these (five intronic, two silent, and seven missense variants) are
classified as not pathogenic (not causing TSC) and three missense
variants (p.K954R, p.S960F, and p.E984Q) are unclassified. One of
the three unclassified missense variants (p.K954R) occurs naturally
in 24/161 vertebrate species analyzed, including 11/83 mammals,
whereas codons 960 (22/161) and 984 (19/161) in the alignment
havedifferent substituted aminoacids to those found inourdatabase
(Supp. Fig. S1A).
The TSC2 LOVD lists 16 different variants (excluding contigu-
ous exon deletions) mapping to exon 31, of which 15 (10 intronic,
one silent, one in-frame indel, and three missense variants) are
classified as not pathogenic. One intronic variant remains unclas-
sified. Amino acids corresponding to the three missense variants
(p.S1276F, p.S1282G, and p.V1291I) occur naturally in one or more
of the vertebrates analyzed (Supp. Fig. S1B).
Our simplemathematical analysis showed that exon 25 has an av-
erage degree of conservation, whereas exon 31 was among the least
conserved. Comparisons of exons 25 and 31 to two other compara-
tively more conserved exons (7 and 22) are shown (Supp. Fig. S2). A
more comprehensive conservation analysis showed agreement with
the simple analysis described above. There was a wide range of con-
servation across the 41 TSC2 exons and the general pattern was
similar with or without fish sequences, apart from a few exceptions
(Supp. Fig. S3A and B). The amino acids encoded by exon 31 were
less conserved on average when compared with those encoded by
exon 25 (Supp. Fig. S3A–D), and the statistical analysis showed that
the distributions of conservation scores for exons 25 and 31 were
significantly lower in value (P < 0.05; Wilcoxon Rank-Sum test) as
compared with the distribution of scores in most of the TSC2 exons
(Supp. Table S1).
Expression Analysis
The first full-length human TSC2 cDNA reported was from
human fetal brain and included exon 25, but not exon 31 [Eu-
ropean Chromosome 16 Tuberous Sclerosis Consortium, 1993].
Exon 31 was subsequently reported in rat and confirmed in
human cDNA [Xu et al., 1995; Kimura et al., 2006]. We
reviewed publications that describe the tissue distribution of
TSC2 transcripts with and without exon 25 in rodents and
in limited human material [Xiao et al., 1995; Xu et al., 1995;
Olsson et al., 1996]. Although exon 25 and the first codon in exon
26 were often absent from TSC2 transcripts in rodents and humans,
most tissues expressed some transcripts containing these sequences
[Xiao et al., 1995; Xu et al., 1995; Olsson et al., 1996]. TSC2 tran-
scripts lacking exon 25 (–ex25) were predominant in samples from
adult human brain and adult human cerebellum [Xu et al., 1995],
whereas human fetal muscle had more transcripts containing exon
25 (+ex25) [Xu et al., 1995]. A quantitative study [Olsson et al.,
1996] estimated the ratio of +ex25:–ex25 in human fetal brain at 1:1;
in three other fetal tissues, the –ex25 transcript was predominant.
Human fetal kidney and fetal brain were found to have mainly the
transcript lacking exon 31 [Xiao et al., 1995].
We searched two databases with TSC2 transcript information:
The Ensembl Genome Browser at http://www.ensembl.org/ and
the National Center for Biotechnology Information Gene database
at http://www.ncbi.nlm.nih.gov/gene/7249. Six of the 26 different
TSC2 transcripts listed in Ensembl were aligned using Clustal
Omega to confirm the exact sequences that were absent from each
transcript. The remaining 20 transcripts were not analyzed as
these are too short to produce a functional protein. In the NCBI
database (Homo sapiens annotation release 106), tracks of intron
spanning TSC2 RNA-sequencing (RNA-seq) reads generated
from alignments of RNA-seq data from the Bodymap2 dataset
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30611)
of 16 adult tissue samples were analyzed. Each tissue in the
Bodymap2 dataset is derived from a different single individual.
To obtain evidence for tissue-specific alternative splicing of TSC2
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exons 25 and 31, we examined tracks of intron spanning RNA-seq
reads for these exons in each Bodymap2 tissue sample. Analysis of
the BodyMap2 tracks showed evidence for the expected sequence
joining each pair of adjacent exons in the majority of reads,
except those involving exons 25 and 31 where a minority of reads
(6% and 11%, respectively) showed a join between adjacent
exons, indicating that transcripts encoding exons 25 and/or 31 are
relatively scarce. Exon 25 was just detectable in heart, lymph node,
skeletal muscle, and thyroid tissue samples, but not detectable in
adipose, adrenal, brain, breast, colon, kidney, liver, lung, ovary,
prostate, testes, or white blood cells. Exon 31 was detectable in
transcripts from adipose, adrenal, brain, breast, colon, kidney, lung,
prostate, skeletal muscle, testes, thyroid, and white blood cells, but
not in heart, liver, lymph node, or ovary.
A similar analysis was performed for 27 different tissues that
are reported in a study of normal adult tissues taken from 95 dif-
ferent individuals [Fagerberg et al, 2014], and are added to the
TSC2 dataset at NCBI (Homo sapiens Annotation Release 107)
[https://goo.gl/Gu0JWq]. Some of the tissues examined in the
BodyMap2 dataset are not included in this study, for example, skele-
tal muscle, breast, and white blood cells. The same tissue type was
analyzed from at least two individuals and exons 25/31 are also just
detectable in some individuals and not evident at all in others. Ag-
gregate reads show that the inclusion of exons 25 and 31 is 7.8%
and 23% of transcripts, respectively, supporting the abundance
of the –ex25 and –ex31 transcripts in adult tissues. Since the tracks
in both studies are from short reads, it was not possible to deter-
minewhether the observation of both exons, for example, in skeletal
muscle and thyroid tissue, indicated that both exons are present in
the same transcript in those tissues. No other TSC2 exons showed
evidence for alternative splicing in these datasets at NCBI.
Analysis of a third RNA-seq dataset from 175 individuals in
the genotype-tissue expression (GTEx) project [GTEx Consortium,
2015] also confirmed the relatively low abundance of TSC2 tran-
scripts containing exons 25 and/or 31 in 51 different tissues from
adults (Supp. Fig. S4; Supp. Tables S2 and S3).
In all the three RNA-seq datasets described above, both exons
25 and 31 are present in very low amounts in adult tissues and
symptoms restricted to specific cell types cannot be excluded if there
is some expression of abnormal +ex25 and/or +ex31 transcripts.
Effects of TSC2 Exon-Specific Deletions and Variants on the
Canonical TSC Complex Function
To investigate the functional importance of exons 25 and 31 com-
pared with other TSC2 exons, we derived a full-length TSC2 expres-
sion construct containing exon 31 (referred to as +ex31) and utilized
existing data from a series of TSC2 expression constructs lacking ex-
ons 3, 4, 5, 6, 9, 12, 19, 22, 25, and 41. These exons have varying num-
bers of confirmed TSC-causing variants (exon 3 [67 variants], exon
4 [50 variants], exon 5 [63 variants], exon 6 [22 variants], exon 9
[64 variants], exon 12 [48 variants], exon 19 [61 variants], exon 22
[35 variants], and exon 41 [18 variants]) and exon 25 has none.
Previous work had shown that three missense variants mapping to
exon 25 (p.R951S, p.R988P [Hoogeveen-Westerveld et al., 2011] and
p.N958S [Hoogeveen-Westerveld et al., 2013]) did not affect TSC
complex function. The TSC1–TSC2 protein interaction is impor-
tant for maintaining the activity of the TSC complex, and therefore
for effective inhibition of TORC1. Reductions in the TSC1 sig-
nals indicate that the TSC1–TSC2 protein interaction is disrupted
[Hoogeveen-Westerveld et al., 2011]. It was observed that deletion
of exons corresponding to the TSC1 interaction domain of the TSC2
protein, or the introduction of a pathogenic amino acid substitu-
tion (TSC2p.R611Q) in this domain, significantly reduced theTSC1
protein signal (Fig. 1B) and prevented the TSC complex-dependent
inhibition of TORC1 activity, as assessed by the T389 phospho-
rylation status of a S6K reporter (Fig. 1C). In contrast, deletion
of TSC2 exon 25 (delex25) or inclusion of exon 31 (+ex31) did not
significantly affect TSC1protein signals (Fig. 1B) or S6K-T389phos-
phorylation (Fig. 1C), compared with the original wild-type TSC2
protein. Also, the presence of sequences corresponding to exon 31
did not rescue the activity of the p.R611Q variant. Therefore, we
did not obtain evidence for a clear functional effect of exons 25 or
31 on TSC complex activity in our assay. Similarly, we did not ob-
tain evidence that either thep.S1282 G1285delinsR (S1282delins) or
p.S1336L variant affected TSC2 protein stability, TSC1–TSC2 pro-
tein interaction, or TSC complex-dependent inhibition of TORC1
activity (Fig. 1A–C). Deletion of exon 25 (delex25) did result in a
nonsignificant reduction in TSC1 protein signals, a nonsignificant
increase in S6K-T389 phosphorylation and a significant decrease in
the total S6K signal. The low S6K signal suggests that the transfec-
tion efficiency for the delex25 variant was reduced compared with
the other variants tested, and it is possible that the deletion of exon
25 sequences might have a subtle effect on TSC complex activity.
Nonetheless, compared with the pathogenic R611Q variant, and the
negative control transfection (TSC1/S6K only), the delex25 variant
was still able to stabilize the TSC1 protein and inhibit TORC1.
Discussion
Clinical diagnosis of TSC can be problematic due to phenotypic
variability, even between affected individuals from the same fam-
ily who have the same TSC-causing variant. Therefore, adding ge-
netic criteria [Northrup et al., 2013] should make TSC diagnosis
less ambiguous. However, the increasing application of NGS-based
gene panels, WES and WGS in diagnostic settings, as well as the
increasing amount of data from large-scale sequencing projects
that include subjects who do not have a definite diagnosis of TSC,
need to be matched with correct variant interpretation. Two of our
cases, neither of whom had a clinical diagnosis of TSC, had stop
variants in exon 25 (TSC2 c.2859dup, p.K954Qfs∗6) and exon 31
(TSC2 c.3837C>G, p.Y1279∗), respectively, that would necessitate
a diagnosis of TSC according to the updated TSC diagnostic crite-
ria [Northrup et al., 2013]. This heightened our awareness to the
downside of automatically associating stop codons in the alterna-
tively spliced TSC2 exons 25 and 31 with TSC.
Defining pathological as “causing TSC,” the only two exons in
TSC2 in which no pathogenic variants have been identified to date
are exons 25 and 31 (www.lovd.nl/TSC2). Therefore, recent reports
of “pathogenic” variants in these alternatively spliced exons led
us to review different strands of evidence to try and ascertain the
functional and clinical importance of these exons and of the putative
“pathogenic” variants reported within them.
First, we examined amino acid sequences in exons 25 and 31 in
multiple species to assess the conservation of these exons that may
shed some light on their relevance to TSC. Although our simple and
statistical analyses suggest that the conservation in these exons is less
compared with themajority of theTSC2 exons, the results still point
to some importance for these exons, possibly in early development
and/or specific tissues.
Next, we investigated the extent to which these exons undergo
alternative splicing. As evident from available data on RNA expres-
sion in adult human tissues, there are tissue-specific differences,
but these support the abundance of the –ex25 and –ex31 transcripts
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Figure 1. Functional assessment. TSC2 expression constructs were derived from the original wild-type construct containing exon 25 but lacking
exon 31 (TSC2), indicated in black. Nonitalicized “TSC2” refers to the protein and is used as such throughout this legend. The pathogenic TSC2
p.R611Q (R611Q) control, and the p.S1282_G1285delinsR (S1282delins) and p.S1336L variants identified in case 3 are indicated. In-frame exon-
specific deletion constructs are referred to as delex3 (for deletion of exon 3), delex4, and so forth. Expression constructs encoding exon 31 are
indicated in gray. TSC2 expression constructs were transfected into HEK 293T cells together with TSC1 and S6K expression constructs. The signals
for TSC2, TSC1, total S6K (S6K), and T389-phosphorylated S6K (T389) were determined per variant, relative to the wild-type control (TSC2) in at least
three independent transfection experiments by immunoblotting, as described previously [Hoogeveen-Westerveld et al., 2011]. Results for cells
transfected with TSC1 and S6K only (TSC1/S6K) are shown for comparison. The mean TSC2 (A), TSC1 (B), and S6K (D) signals and mean T389/S6K
ratio (C) are shown. In each case, the dotted line indicates the signal or ratio corresponding to wild-type TSC2 (+exon 25; −exon 31) (TSC2; = 1.0).
Error bars represent the standard error of the mean; variants that showed significant differences from the wild-type control (TSC2; +exon 25; −exon
31) are indicated with an asterisk (P < 0.05; Student’s t-test). A: Mean signals for the TSC2 variants, relative to wild-type TSC2 (+exon 25; −exon 31).
Note that the TSC2 signal is significantly reduced by deletion of exons 3, 4, 5, or 22, or by the pathogenic R611Q substitution. Deletion of sequences
corresponding to exon 41 (delex41) removes the epitope recognized by the antibody used for TSC2 detection. B: Mean TSC1 signals in the presence
of the TSC2 variants relative to wild-type TSC2 (+exon 25; −exon 31). TSC1 signals were significantly reduced in the presence of the delex3, 4, 5, 6,
9, 12, 19, and 22 variants, and in the presence of the TSC2 R611Q substitution. C: Mean T389/S6K ratios in the presence of the TSC2 variants, relative
to wild-type TSC2 (+exon 25; −exon 31). The T389/S6K ratios were significantly increased in the presence of the R611Q, delex3, 4, 5, 6, 9, 12, 19, 22
and 41 variants, as well as in the absence of TSC2 (TSC1/S6K).D: Mean total S6K signals in the presence of the TSC2 variants, relative to wild-type
TSC2 (+exon 25; −exon 31).
(Supp. Figs. S4 and S5; Supp. Table S3). It was difficult to find
data comparing the same human adult and fetal tissue types. In
the mouse, the +ex25 transcript was more abundant in fetal and
neonatal brain, whereas adult brain had an abundance of the –ex25
transcript [Xu et al., 1995; Olsson et al., 1996]. This agrees with
tissue-specific expression data showing predominantly the –ex25
transcript in adult human brain [https://goo.gl/6V7PpS] and could
point to some relevance in stage-specific development. More infor-
mation on transcript and tissue-specific expression of TSC2 in the
human fetus could help clarify the relative importance and specific
functions of the different transcripts. Nonetheless, the evidence re-
viewed here leaves no doubt that TSC2 transcripts lacking exon 25
or 31 exist and suggest that they form the majority of TSC2 tran-
scripts in a wide range of adult human tissues, including those, such
as brain, important in TSC.
Finally, we investigated the influence of the amino acid sequences
corresponding to exons 25 and 31 on TSC complex function. We
used a previously described functional test that assays the effect
of the TSC complex on TORC1 activity [Hoogeveen-Westerveld
et al., 2011, 2013]. According to this assay, the amino acids
encoded by TSC2 exons 25 and 31 are not required for TSC com-
plex function. Furthermore, we did not obtain any evidence that the
p.S1282 G1285delinsR or p.S1336L variants significantly affected
TSC complex function. Also, none of the tested variants that map to
exon 25 affect TSC complex function [Hoogeveen-Westerveld et al.,
2011, 2013].
Our analysis indicates that variants within TSC2 exon 25 or
31 do not inactivate the TSC complex and are unlikely to cause
TSC. Coincidentally, just prior to submission of this manuscript,
a batch of data submitted to the TSC databases was found to con-
tain the same exon 31 variant (TSC2 c.3846 3855delinsG) as in case
3. This in-frame deletion co-occurs with a definite TSC-causing
variant in TSC2 exon 5 (TSC2 c.569dup, p.Y190∗) in an infant
who fulfils the diagnostic criteria for TSC (cortical tubers, SEGA,
subependymal nodules, hypomelanotic macules, renal angiomy-
olipoma, epilepsy). The exon5 and exon31 variants (TSC2 c.569dup
andTSC2 c.3846 3855delinsG)areboth inherited fromaparentwho
also has clinical TSC (hypomelanoticmacules, facial angiofibromas,
cortical tubers, epilepsy, intellectual disability, and renal angiomy-
olipomas). This new case is consistent with our assertion that TSC2
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c.3846 3855delinsG on its own is not the cause of classical TSC.
Nonetheless, it is possible that variants mapping to TSC2 exon 25
or 31 might have a significant role in disease. For example, a role
for the TSC2 c.2859dup (p.K954Qfs∗6) and c.3846 3855delinsG
(p.S1282 G1285delinsR) variants in epilepsy cannot be excluded.
The TSC2 c.3846 3855delinsG variant has been identified in several
other individuals with infantile epilepsy who are without clinical
features of TSC (Panzer, 2015, unpublished data). Exons 25 and
31 encode consensus sites of AKT and AMPK phosphorylation, re-
spectively (http://scansite3.mit.edu) [Yaffe et al., 2001]. The TSC2
protein is inactivated by AKT phosphorylation [Manning et al.,
2002] and activated by AMPK phosphorylation [Inoki et al., 2006].
It is possible that these exons alter the activity or response to stimuli
of the TSC complex, particularly during fetal development. More
sensitive assays of TSC complex activity are required to compare the
activities of the different TSC2 protein splice isoforms and variants
in more detail.
The findings reported here are specific to TSC2 exons 25 and 31,
as stop variants that definitely cause TSC have been identified in all
other TSC2 exons. Additional evidence that variants within exon 31
do not cause TSC comes from reports of three truncating variants
(two frameshift and one nonsense) in the EVS and ExACpopulation
databases (Supp. Table S4). Although phenotype information is not
available, the population frequencies are quite high (1:532–1:1,443
individuals), which supports our conclusion that these truncating
variants do not cause TSC. The exon 25 and 31 cases described here
show the need to exercise caution when assigning pathogenicity,
especially if the variant found has never been shown to cause TSC
in a patient with a firm clinical diagnosis. This caution is probably
reasonable in many other diseases.
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